share_log

Redhill Biopharma | 6-K: Report of foreign private issuer (related to financial reporting)

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Redhill Biopharma | 6-K：外国发行人报告
美股sec公告 ·  04/03 07:02
Moomoo AI 已提取核心信息
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has entered into a Securities Purchase Agreement with private investors on March 29, 2024. The agreement involves the issuance and sale of 2,144,487 American Depositary Shares (ADSs) and warrants to purchase an equivalent number of ADSs. Each ADS represents 400 ordinary shares of RedHill, with the purchase price set at $0.58289 per ADS and accompanying warrant. The warrants are exercisable at $0.75 per ADS and are valid for five years from the issuance date. The offering is expected to close on April 3, 2024, subject to customary closing conditions, and aims to raise gross proceeds of $1.25 million before offering expenses. This offering is part of a 'shelf' registration statement filed with the SEC on July 29, 2021, and declared effective on August 9, 2021. No placement agent was involved in the offering. The final prospectus supplement and accompanying prospectus will be filed with the SEC and will be available on their website.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has entered into a Securities Purchase Agreement with private investors on March 29, 2024. The agreement involves the issuance and sale of 2,144,487 American Depositary Shares (ADSs) and warrants to purchase an equivalent number of ADSs. Each ADS represents 400 ordinary shares of RedHill, with the purchase price set at $0.58289 per ADS and accompanying warrant. The warrants are exercisable at $0.75 per ADS and are valid for five years from the issuance date. The offering is expected to close on April 3, 2024, subject to customary closing conditions, and aims to raise gross proceeds of $1.25 million before offering expenses. This offering is part of a 'shelf' registration statement filed with the SEC on July 29, 2021, and declared effective on August 9, 2021. No placement agent was involved in the offering. The final prospectus supplement and accompanying prospectus will be filed with the SEC and will be available on their website.
专业生物制药公司RedHill Biopharma Ltd. 已于2024年3月29日与私人投资者签订了证券购买协议。该协议涉及发行和出售2,144,487股美国存托股票（ADS）和购买等量美国存托证券的认股权证。每股ADS代表RedHill的400股普通股，收购价格定为每股ADS和附带的认股权证0.58289美元。认股权证的行使价格为每份ADS0.75美元，自发行之日起五年内有效。此次发行预计将于2024年4月3日结束，但须遵守惯例成交条件，目标是在发行费用前筹集125万美元的总收益。本次发行是2021年7月29日向美国证券交易委员会提交的 “货架” 注册声明的一部分，该声明于2021年8月9日宣布生效。没有配售代理人参与此次发行。最终的招股说明书补充文件和随附的招股说明书将提交给美国证券交易委员会，并将在其网站上公布。
专业生物制药公司RedHill Biopharma Ltd. 已于2024年3月29日与私人投资者签订了证券购买协议。该协议涉及发行和出售2,144,487股美国存托股票（ADS）和购买等量美国存托证券的认股权证。每股ADS代表RedHill的400股普通股，收购价格定为每股ADS和附带的认股权证0.58289美元。认股权证的行使价格为每份ADS0.75美元，自发行之日起五年内有效。此次发行预计将于2024年4月3日结束，但须遵守惯例成交条件，目标是在发行费用前筹集125万美元的总收益。本次发行是2021年7月29日向美国证券交易委员会提交的 “货架” 注册声明的一部分，该声明于2021年8月9日宣布生效。没有配售代理人参与此次发行。最终的招股说明书补充文件和随附的招股说明书将提交给美国证券交易委员会，并将在其网站上公布。
有用
没用

该公告为独立文件：

独立文件1

独立文件2

独立文件3

独立文件4

独立文件5

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息